• Norepinephrine and epinephrine are catecholamines CA release

  2024-10-30

  

  Norepinephrine and epinephrine are catecholamines (CA) released from synaptic nerves and the adrenal gland that mediate systemic responses to nutritional stressors (Cannon and De la Paz, 1911). CA mobilize plasma glucose by suppressing insulin secretion from the pancreatic β-cell (Katada and Ui, 198

• The disease stimulatory effects of hyperadiponectinemia in p

  2024-10-30

  

  The disease-stimulatory effects of hyperadiponectinemia in patients contradict a previous view based on studies of preclinical models showing that APN might be beneficial for AD [8]. Indeed, despite the action of APN as a risk factor in patients with AD, APN is protective against oxidative stress-in

• Additionally regulation of GPCR heteromerization by specific

  2024-10-30

  

  Additionally, regulation of GPCR heteromerization by specific ligands may depend not only on the affinity of ligands for receptors, but also on presence of different interacting proteins co-localizing with the receptors in the specific cell, which may induce some conformational changes and contribut

• br Concluding Remarks The effects of

  2024-10-30

  

  Concluding Remarks The effects of point mutations of the four ARs on ligand binding affinities, functional potencies, and efficacies constitute a valuable source of pharmacological information. We analyzed the existing data and mapped it on the collection of available AR crystal structures, allow

• ADOR immunoreactivity was high in parasympathetically innerv

  2024-10-30

  

  ADOR immunoreactivity was high in parasympathetically-innervated smooth muscle, namely the iris sphincter muscle and the ciliary muscle. No ADOR immunoreactivity was noted in the sympathetically-innervated iris dilator muscle. Immunoreactivity against all four ADORs was noted in the ciliary epitheli

• br AD and COX LOX

  2024-10-29

  

  AD and COX/5-LOX pharmacology Early studies on the role of cyclooxygenases in AD were inspired by epidemiological data suggesting that COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) could be beneficial in AD patients (Lucca et al., 1994, McGeer et al., 1990). This line of re

• It has also been reported that

  2024-10-29

  

  It has also been reported that defects in ATM or ATR signalling are synthetically lethal with PARP inhibition (Turner et al., 2008, Peasland et al., 2011, Yap et al., 2011, Michels et al., 2014), suggesting that combined inhibition of PARP and ATM or ATR may be an effective therapeutic strategy. In

• br ASK in multiple sclerosis and optic neuritis

  2024-10-29

  

  ASK1 in multiple sclerosis and optic neuritis Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system (CNS), is the most common neurological disease among young adults in the United States and Europe (Dutta and Trapp, 2011). Although MS primarily affect

• br Experimental br Acknowledgment This paper was financially

  2024-10-29

  

  Experimental Acknowledgment This paper was financially supported by the Project Funded by China Postdoctoral Science Foundation (2017T100186), Natural Science Foundation of Liaoning Province (20170540858), General Scientific Research Projects of Department of Education of Liaoning Province (20

• Patients with cardiovascular disorders typically

  2024-10-29

  

  Patients with cardiovascular disorders typically have lower plasma apelin levels than matched healthy controls. For example, plasma apelin levels are reduced in patients with coronary artery disease (CAD), and among CAD patients with unstable angina or acute myocardial infraction there is a further

• To investigate if WP increased CAT activity in cells C

  2024-10-29

  

  To investigate if WP increased CAT activity in cells, C2C12 muscle (+)-Apogossypol receptor were treated with 0.1 to 0.4 mg/mL of WP (80.05% protein) for 24 h and then stressed with 0.75 mM H2O2 for 1 h (Xu et al., 2011). The CAT activity was significantly enhanced from 15.1 ± 0.7 to 23.7 ± 1.3 U/mg

• The current results also demonstrated tendencies toward decr

  2024-10-29

  

  The current results also demonstrated tendencies toward decreased serum Aβ40 levels and increased Aβ42 levels during the 1-year follow-up. These tendencies are consistent with the results of a previous study that evaluated Aβs in the CSF of patients with late-life depression (Pomara et al., 2016). T

• Bax inhibitor peptide P5 In order to postulate its binding m

  2024-10-29

  

  In order to postulate its binding mode in APN, Bax inhibitor peptide P5 13v was docked into the active site of APN (PDB code: 2DQM) using Sybyl_X 1.3. As illustrated in Fig. 5A, the catalytic zinc ion of APN was chelated by the hydroxamate moiety of 13v, and the S1, S1′ and S2′ pockets of APN were o

• In large biopsies series from ALK NSCLC

  2024-10-28

  

  In large biopsies series from ALK+ NSCLC treated patients, the number of detected mutations increased after second generation ALKi (Gainor et al., 2016) and in one study were present in 56% of the entire cohort (Shaw et al., 2013b). For example, the rate of G1202R mutations increases from 2% in pos

• The ORR obtained with crizotinib on our cohort was low

  2024-10-28

  

  The ORR obtained with crizotinib on our cohort was low compared to other studies, such as the prospective studies of A. Shaw et al. (ORR = 65% in second line), B. Solomon et al. (ORR = 74% in first line) and the more comparable large retrospective study of M. Duruisseaux et al. on the French CLINALK

16090 records 65/1073 page Previous Next First page 上5页 6162636465 下5页 Last page